妇科肿瘤化疗防治恶心呕吐药物的应用评价  

Application Evaluation of Drugs for Prevention and Treatment of Nausea and Vomiting in Gynecologic Neoplasms Chemotherapy Patients

作　　者：梅洪梁 张海霞[1] 葛卫红[1] MEI Hongliang;ZHANG Haixia;GE Weihong(Department of Medication,the Affiliated Drum Tower Hospital of Nanjing University Medical School,Nanjing 210008)

机构地区：[1]南京大学医学院附属鼓楼医院药学部,南京210008

出　　处：《药学与临床研究》2018年第6期431-434,共4页Pharmaceutical and Clinical Research

摘　　要：对妇科恶性肿瘤化疗防治恶心呕吐药物应用的合理性评价。收集本院妇科2018年4月接受化疗的住院患者病历111份,根据国内外肿瘤相关的恶心呕吐防治指南,分析应用防治恶心呕吐药物存在的问题。100例(90.09%)地塞米松(DXM)应用不合理;111例(100%)均应用5-羟色胺3受体拮抗剂,其中79例(71.17%)应用疗程不合理,17例(15.32%)超致吐风险级别用药,4例(3.60%)重复应用;104例(93.69%)无指征应用H2受体拮抗剂或质子泵抑制剂。化疗患者呕吐防治药物的应用存在不合理现象,建议加强医嘱审核,提高应用呕吐防治药物的合理性。This study is to evaluate the rationality of the application of drugs for preventing and treating nausea and vomiting in patients with gynecologic malignancies undergoing chemotherapy.A total of 111 medical records were collected from patients who received chemotherapy in April 2018 to analyze the problems of drug use for prevention and treatment of nausea and vomiting according to domestic and foreign guidelines.The application of dexamethasone in 100 cases(90.09%)was not reasonable.Among the 111 cases(100%)used 5-hydroxytryptamine 3 receptor antagonist,79 cases(71.17%) were unreasonable for course,17 cases(15.32%) were over risk level,4 cases(3.60%)were repeated.There were 104(93.69%) patients using H2 receptor antagonist or proton pump inhibitor without indications.The application of medicine for prevention and treatment of vomiting in patients under gynecologic tumor chemotherapy were generally unreasonable.It suggested that clinical pharmacists should strengthen medical advice review,improve the rationality of medicine and ensure the safety of patients.

关 键 词：妇科肿瘤 化疗 防治恶心呕吐药物 应用评价 合理用药 

分 类 号：R975.4[医药卫生—药品]